12.05.2021 09:28:00

Member of Immunovia's Board of Directors purchases shares in the company

LUND, Sweden, May 12, 2021 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") announced today that the member of the Board of Directors Peter Høngaard Andersen has almost doubled his ­­­­shareholding in Immunovia by purchasing 2,730 shares, an investment of 297,570 SEK. After the purchase, the holding amounts to 5,730 shares.

For more information, please contact:

Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com 
Tel: +46 73 376 76 64

About Immunovia

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. The final validation study was completed in Q1 2021. The accreditation process forImmunovia Inc. in Marlborough, Massachusetts, USA is ongoing and commercial testing will begin in Q2 after the accreditation. The European launch plan will be communicated Q2 2021.

IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. The test will be exclusively provided by Immunovia Inc., Marlborough,Massachusetts, USA.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/member-of-immunovia-s-board-of-directors-purchases-shares-in-the-company,c3345890

The following files are available for download:

https://mb.cision.com/Main/13121/3345890/1416677.pdf

Press release (PDF)

Cision View original content:http://www.prnewswire.com/news-releases/member-of-immunovias-board-of-directors-purchases-shares-in-the-company-301289477.html

SOURCE Immunovia AB

Nachrichten zu Immunovia ABmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Immunovia ABmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Immunovia AB 0,62 4,20% Immunovia AB